XPO1 and acute myeloid leukemia: Additionally, we interrogated the causal linkage of the presence/absence of mtNPM1 on therapy responsiveness to standard anti-AML agents, including cytarabine and daunorubicin, as well as to novel agents, including MI, exportin-1 inhibitor (KPT-330) [13], arsenic trioxide or ATRA (all-trans-retinoic acid) [28].